Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 18,500 shares, a growth of 203.3% from the December 31st total of 6,100 shares. Based on an average daily trading volume, of 10,700 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.2% of the company’s stock are short sold.

Armata Pharmaceuticals Trading Up 1.9 %

Shares of NYSEAMERICAN ARMP traded up $0.04 during trading hours on Wednesday, reaching $2.12. 792 shares of the stock traded hands, compared to its average volume of 10,719. The stock has a market cap of $76.70 million, a price-to-earnings ratio of -1.29 and a beta of 0.85. Armata Pharmaceuticals has a 52-week low of $1.80 and a 52-week high of $4.48.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research note on Thursday, December 19th.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.